229 related articles for article (PubMed ID: 31154533)
1. Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.
Triarico S; Capozza MA; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Support Care Cancer; 2019 Oct; 27(10):3639-3645. PubMed ID: 31154533
[TBL] [Abstract][Full Text] [Related]
2. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
[TBL] [Abstract][Full Text] [Related]
3. [Cancer breakthrough pain. Indications for rapidly effective opioids].
Kessler J; Bardenheuer HJ
Anaesthesist; 2011 Jul; 60(7):674-82. PubMed ID: 21491140
[TBL] [Abstract][Full Text] [Related]
4. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
5. The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
Coombes L; Burke K; Anderson AK
Scand J Pain; 2017 Oct; 17():256-259. PubMed ID: 29229211
[TBL] [Abstract][Full Text] [Related]
6. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl pectin nasal spray for breakthrough cancer pain.
Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
[No Abstract] [Full Text] [Related]
8. Fentanyl for breakthrough pain: a systematic review.
Davis MP
Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
10. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based treatment of cancer-related breakthrough pain with opioids.
Zeppetella G
J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
[TBL] [Abstract][Full Text] [Related]
12. [Intranasal delivery of systemic drugs: a new route for opioid drugs].
Devillier P; Grassin-Delyle S; Naline E; Buenestado A; Blouquit-Laye S; Advenier C
Therapie; 2010; 65(5):475-81. PubMed ID: 21144483
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
14. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
15. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
16. Patient satisfaction with intranasal fentanyl for breakthrough pain.
Veldhorst-Janssen NM; Fiddelers AA; Zandstra H; Kessels AG; Zandstra H; Marcus MA; Neef C; van der Kuy PH
J Palliat Med; 2012 Jun; 15(6):631-2. PubMed ID: 22656053
[No Abstract] [Full Text] [Related]
17. Optimal management of breakthrough cancer pain (BCP).
Escobar Y; Mañas A; Juliá J; Gálvez R; Zaragozá F; Margarit C; López R; Casas A; Antón A; Cruz JJ
Clin Transl Oncol; 2013 Jul; 15(7):526-34. PubMed ID: 23263914
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
[TBL] [Abstract][Full Text] [Related]
19. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
[TBL] [Abstract][Full Text] [Related]
20. The pharmacoeconomics of breakthrough cancer pain.
Kuo KL; Saokaew S; Stenehjem DD
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
